https://www.selleckchem.com/btk.html
Hypofractionated radiotherapy for prostate cancer reduces the inconvenience of an extended treatment course but the appropriate treatment margin to ensure tumor control while minimizing toxicity is not standardized. Using a novel dose accumulation workflow with iterative CBCT (iCBCT) images, we were able to validate treatment margins. Sixteen patients treated to the prostate on a hypofractionated clinical trial were selected. Prescription dose was 3625cGy to95% of the PTV in 5 fractions with a boost to 4000cGy to the high risk GTV (if applicable
Like
Comment
Share
